Johnson & Johnson ROE 2006-2018 | JNJ

Current and historical return on equity (ROE) values for Johnson & Johnson (JNJ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Johnson & Johnson ROE for the three months ending September 30, 2018 was 34.97%.
Johnson & Johnson ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $1.54B $0.00B 3.31%
2018-06-30 $1.37B $62.89B 2.11%
2018-03-31 $1.25B $63.26B 1.85%
2017-12-31 $1.30B $60.16B 1.88%
2017-09-30 $15.83B $73.98B 22.08%
2017-06-30 $16.34B $71.92B 22.89%
2017-03-31 $16.51B $70.34B 23.08%
2016-12-31 $16.54B $70.42B 22.95%
2016-09-30 $15.94B $72.77B 22.06%
2016-06-30 $15.03B $72.47B 20.88%
2016-03-31 $15.55B $72.65B 21.71%
2015-12-31 $15.41B $71.15B 21.88%
2015-09-30 $14.72B $71.55B 21.00%
2015-06-30 $16.11B $71.13B 22.58%
2015-03-31 $15.92B $67.88B 21.78%
2014-12-31 $16.32B $69.75B 21.69%
2014-09-30 $17.32B $76.59B 22.70%
2014-06-30 $15.55B $78.05B 20.84%
2014-03-31 $15.06B $76.58B 20.77%
2013-12-31 $13.83B $74.05B 19.73%
2013-09-30 $12.88B $69.80B 19.00%
2013-06-30 $12.87B $69.67B 19.41%
2013-03-31 $10.44B $66.86B 16.32%
2012-12-31 $10.85B $64.83B 17.34%
2012-09-30 $8.50B $63.76B 14.02%
2012-06-30 $8.74B $60.43B 14.54%
2012-03-31 $10.11B $61.37B 16.70%
2011-12-31 $9.67B $57.08B 16.08%
2011-09-30 $11.40B $61.53B 18.99%
2011-06-30 $11.61B $62.13B 19.69%
2011-03-31 $12.28B $59.86B 21.69%
2010-12-31 $13.33B $56.58B 24.28%
2010-09-30 $13.60B $57.29B 25.46%
2010-06-30 $13.53B $52.85B 26.17%
2010-03-31 $13.29B $52.91B 26.55%
2009-12-31 $12.27B $50.59B 25.69%
2009-09-30 $12.77B $50.38B 27.93%
2009-06-30 $12.74B $46.25B 28.58%
2009-03-31 $12.86B $43.79B 28.82%
2008-12-31 $12.95B $42.51B 28.73%
2008-09-30 $12.61B $45.73B 27.85%
2008-06-30 $11.85B $46.44B 26.48%
2008-03-31 $11.60B $45.63B 26.42%
2007-12-31 $10.58B $43.32B 24.75%
2007-09-30 $10.37B $43.57B 24.85%
2007-06-30 $10.58B $43.12B 25.82%
2007-03-31 $10.32B $40.93B 25.55%
2006-12-31 $11.05B $39.32B 27.33%
2006-09-30 $10.98B $40.57B 27.25%
2006-06-30 $10.76B $40.74B 27.34%
2006-03-31 $10.53B $41.12B 27.73%
2005-12-31 $10.06B $38.71B 27.87%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $373.058B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $264.902B 15.51
Novartis AG (NVS) Switzerland $202.059B 17.26
Merck (MRK) United States $195.069B 17.23
AbbVie (ABBV) United States $133.211B 13.01
Eli Lilly (LLY) United States $120.201B 22.25
Sanofi (SNY) France $111.785B 14.15
Novo Nordisk (NVO) Denmark $105.487B 16.86
GlaxoSmithKline (GSK) United Kingdom $101.355B 13.53
AstraZeneca (AZN) United Kingdom $99.315B 10.92
Bristol-Myers Squibb (BMY) United States $88.755B 16.07